AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
How Lior Wilczynski turned her immigrant roots into a $150 million fintech exit
2
Why I decided not to become the CEO of the company I founded
3
Intel caps year from hell with worst-ever stock performance
4
“Israel exits this war more powerful and stable than ever,” say Glilot Capital Partners
5
Defense tech is booming—but who will actually win?
More news

Kåre Schultz

9 stories about Kåre Schultz
מנכ"ל טבע החדש קור שולץ 2

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
מנכ"ל טבע החדש קור שולץ 2

Israeli Parliamentarians to Push Against Teva Layoffs in the Country

26.11.17|Dror Reich and Maayan Manela
Shelly Yachimovich, a member of the Israeli parliament representing the Israeli Labor Party, said she intends to call an emergency hearing of the Israeli parliament’s state control committee on the issue. The planned layoffs are a result of the company’s management failures, she added
מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
מנכ"ל טבע החדש קור שולץ 2

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer
Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
מנכ"ל טבע החדש קור שולץ 2

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
מנכ"ל טבע החדש קור שולץ

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles